NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third quarter revenues increased 25 percent year over year, beating Wall Street estimates on the top and bottom line.

The San Diego-based genetic analysis tools firm reported total revenues of $357 million, up from $285.9 million for Q3 2012, and surpassing the Wall Street consensus estimate for revenues of $343.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.